Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum]
Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D. Clinicoecon Outcomes Res. 2017;9:173–179. On page 174, Methods section, 1st paragraph, the last sentence reads “The percentage of patients eligible for dual therapy (ATV+r+3TC) was derived f...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2017-04-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D. Clinicoecon Outcomes Res. 2017;9:173–179. On page 174, Methods section, 1st paragraph, the last sentence reads “The percentage of patients eligible for dual therapy (ATV+r+3TC) was derived from the Atlas-M trial at 48 weeks,20 in which patients were eligible to simplification if aged >17 years, receiving for at least 6 months ATV+r+2 NRTI, with “at least two HIV-RNA levels <50 copies/mL on two consecutive determinations at least 3 months apart,” for at least 6 months with a CD4 cell count >200 cells/mm3, no history of AIDS-related events in the year before enrollment.”. The correct sentence is “The percentage of patients eligible for dual therapy (ATV+r+3TC) was derived from the Atlas-M trial at 48 weeks,20 in which patients were eligible to simplification if aged ≥18 years, receiving for at least 6 months ATV+r+2 NRTI, with “at least two HIV-RNA levels <50 copies/mL on two consecutive determinations at least 3 months apart,” for at least 6 months with a CD4 cell count >200 cells/mm3, no history of AIDS-related events in the year before enrollment.”.Read the original article |
|---|---|
| Item Description: | 1178-6981 |